Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA.Business Wire (press release)THINK (THerapeutic Immunotherapy with NKR-2) is a multinational (EU/US) open-label Phase Ib study to assess the safety and clinical activi… Continue reading
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA.Business Wire (press release)THINK (THerapeutic Immunotherapy with NKR-2) is a multinational (EU/US) open-label Phase Ib study to assess the safety and clinical activi… Continue reading
MIT Technology Review |
Gene Therapy in a Box
MIT Technology Review Jennifer Adair carried out her first gene therapy experiment several years ago. A cancer treatment, it involved collecting blood from a patient, and then adding to these cells a new strand of DNA—a gene—that would protect them from a powerful … |
|
Editas Medicine Announces Fourth Quarter and Full Year 2016 Results and Update
EconoTimes “In 2016, we significantly broadened our scientific platform with CRISPR/Cpf1 and advanced forms of CRISPR/Cas9, demonstrated proof-of-editing in vivo for our most advanced program in LCA10, and expanded our leadership team with the addition of our … |
Genetic Literacy Project |
Green genes: Germany’s top organic researcher says environmentalists should embrace sustainable CRISPR gene …
Genetic Literacy Project [Editor’s note: The following is a Q&A with Urs Niggli, director of the Research Institute for Organic Agriculture in Germany. It has been translated from German by Google.] New techniques are currently revolutionizing genetic research. They allow … |
Curetoday.com |
Zeroing In on CAR T-Cell Therapy
Curetoday.com Then, a treatment counselor at the Leukemia and Lymphoma Society suggested a clinical trial of chimeric antigen receptor T–cell (CAR T) therapy, a new technique in which doctors extract some of a patient’s immune cells, alter them, and then re-infuse … |
|
Dosing underway in REGENXBIO’s early-stage study of gene therapy RGX-501 in HoFH
Seeking Alpha The first patient has been dosed in REGENXBIO’s (NASDAQ:RGNX) Phase 1/2 clinical trial assessing gene therapy RGX-501 for the treatment of homozygous familial hypercholesterolemia (HoFH). Interim results are expected by year-end. The trial is an … REGENXBIO Announces Initiation of Phase I/II Clinical Trial of RGX-501 for the Treatment of Homozygous Familial …Yahoo Finance |